cipla

  1. M

    InvaGen Pharmaceuticals Receives USFDA's Form 483 – Addressing Observations

    New Delhi, February 10 Drug maker Cipla said that the US health regulator has issued Form 483 with two observations after inspecting a manufacturing facility of its US-based unit, InvaGen Pharmaceuticals, Inc.A Pre-Approval Inspection was conducted by the US Food and Drug Administration...
Back
Top